Better Health for All

BioMarin's core business is developing therapies for serious and life-threatening rare genetic diseases, addressing unmet medical needs.

As of year-end 2024, the company provided therapies to approximately 14,000 patients worldwide, with 8 approved products and 5 in R&D. There is no evidence of revenue from products with established negative health outcomes. The company had no FDA GCP inspection findings, recalls, cGMP enforcement actions, or safety alerts in 2023 or 2024. However, specific product data indicates adverse events: VOXZOGO clinical trials showed transient decreases in blood pressure in 13% of treated patients and injection site reactions in 85%, with 2 patients discontinuing treatment due to pain/anxiety. BRINEURA has observed infusion-associated reactions including hypersensitivity. BioMarin offers patient assistance programs, with 96% of eligible families paying $0 out-of-pocket for VOXZOGO prescriptions, covering up to $18,200 annually. These programs are not valid for government-funded insurance and are limited to commercially insured patients. The company is reaching national pricing agreements with some low- and middle-income countries. BioMarin's Corporate Compliance Program includes training on data privacy and a hotline for reporting concerns. The company focuses on product candidates that provide an opportunity to be first-to-market. BioMarin RareConnections offers disease and product education. The Corporate Compliance Program limits gifts to healthcare professionals to $3,500 annually.

Fair Money & Economic Opportunity

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing therapies for rare genetic diseases. Its core business does not involve offering lending or deposit services, consumer credit products, or managing customer financial data. While the company does focus on medically underserved populations and offers patient assistance programs for medication costs, these activities do not align with the financial services context of the 'Fair Money & Economic Opportunity' KPIs.

Therefore, all KPIs related to financial services, such as underserved client share in lending, pricing fairness (APRs), exploitative fees, loan inclusion initiatives, financial data accessibility, fair lending compliance, wealth building outcomes from financial products, profit reinvestment in community finance, financial literacy programs, debt burden ratios, geographic inclusion of financial access points, and product simplicity of financial offerings, are not applicable to its business model.

Fair Pay & Worker Respect

No relevant data was found in the provided articles to assess BioMarin Pharmaceutical Inc. against the 'Fair Pay & Worker Respect' ethical value. The articles either did not contain information pertaining to workforce practices

or were inaccessible.

Fair Trade & Ethical Sourcing

BioMarin has not identified any instances of modern slavery in its operations or supply chains as of the financial year ended December 31, 2024.

The company's Supplier Code of Conduct sets expectations for suppliers regarding safe working conditions and respect for workers, and BioMarin conducts regular compliance audits of its materials and service providers.

Honest & Fair Business

BioMarin Pharmaceutical Inc. has a whistleblower policy with a toll-free hotline for anonymous reporting, and all employees receive initial and annual compliance training and certification on the Global Code of Conduct.

However, the effectiveness of the program is not publicly measured. The Science Committee is comprised solely of independent directors, but the percentage of the overall board that is conflict-free is not specified. BioMarin has an Anti-Bribery and Anti-Corruption (ABAC) policy and conducts annual training for all employees, but the effectiveness metrics are not provided. The company also states it conducts auditing and monitoring activities to assess compliance and will work with an independent consultant by December 31, 2024, to strengthen internal audit and control functions, including public disclosure accuracy.

Kind to Animals

BioMarin conducts pre-clinical trials on animals for drug testing and approval.

The company's policy states that animal testing should be performed after considering methods to reduce the number of animals used and refine procedures to minimize distress, and that alternatives should be used wherever possible, scientifically valid, and acceptable to regulators. BioMarin does not provide support for animal model studies through its external research program. The company uses 50,000–100,000 animals annually in testing, with no transparent reduction targets.

Planet-Friendly Business

BioMarin reported zero environmental compliance violations in both 2023 and 2024.

The company also maintains ISO 50001 certification for its Shanbally, Ireland energy management system since 2017.

Respect for Cultures & Communities

BioMarin partners with more than 200 advocacy groups worldwide.

The company has no reported cultural appropriation incidents. A formal mechanism is available for all stakeholders to report concerns to the Board of Directors via postal mail or an online form. Annually, all employees are required to read, understand, and certify adherence to the company's Code of Conduct, which outlines global ethical responsibilities.

Zero Waste & Sustainable Products

BioMarin has not incurred any waste disposal violations in the past three years, as indicated by the absence of such reports in the provided articles, including the SASB alignment report covering 2023-2024.

The company has established waste reduction targets as part of its Energy Management System (EnMS) framework. BioMarin's Supplier Code of Conduct highlights expectations that suppliers utilize sound and environmentally sustainable business practices, which includes waste-related requirements for all tier-1 suppliers.